Welcome to our dedicated page for Meihua International Medical Technologies Co., Ltd. SEC filings (Ticker: MHUA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Meihua International Medical Technologies Co., Ltd. filings document the regulatory record of a Cayman Islands foreign private issuer with operating subsidiaries in China and a disposable medical-device business. Recent Form 6-K reports cover material events, shareholder meeting materials, proxy matters, auditor changes, and capital-structure actions involving its ordinary and Class A ordinary shares.
The company's filings also describe Nasdaq delisting proceedings, the suspension of its Class A ordinary shares from Nasdaq trading, OTC Marketplace trading under the symbol MHUAF, securities purchase agreements, private placement closings, lock-up and leak-out agreements, share consolidation mechanics, governance approvals, and related exhibit documents.
Meihua International Medical Technologies Co., Ltd. director Jia Wenzhang reported an existing option position in a Form 3/A amendment. The filing shows a stock option with an exercise price of $530.0000 per share, linked to 19.0000 shares of common stock and expiring on June 27, 2032. Following this report, the option position covers a total of 19.0000 underlying common shares held directly.
Meihua International Medical Technologies Co., Ltd. reported that Jia Wenzhang, serving as an Independent Director, filed an initial Form 3 statement of beneficial ownership. The filing shows no reported transactions and no derivative positions, reflecting only the person’s status as a reporting insider.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for reporting person Colin Anna, who serves as an Independent Director of the company. This filing is an initial statement of beneficial ownership and does not report any stock purchases, sales, option exercises, or other transactions.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for officer Wang Ailiang, who is listed as Chairwoman. The filing reports no insider transactions, no current share holdings, and no outstanding derivative positions for her at this time.
Meihua International Medical Technologies Co., Ltd. CEO Lee Leyi has filed an initial insider ownership report on Form 3. The data provided shows no reported transactions or derivative positions, and no current holding entries are listed for this reporting person.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for its CFO, Liao Shilong, reporting his beneficial ownership status in the company’s securities. The filing shows no reported transactions, no reported share acquisitions or dispositions, and no listed derivative positions at the time of this statement.
Meihua International Medical Technologies reports that Nasdaq has moved forward with delisting its securities. Nasdaq staff initially determined to delist the shares in December 2025, and trading of the Company’s class A ordinary shares was suspended and moved to the OTC Marketplace under the symbol “MHUAF” on December 9, 2025.
The Company appealed and attended a hearing before a Nasdaq Hearings Panel on January 27, 2026, but on February 24, 2026 the Panel denied the request to reinstate trading and determined to delist the securities. On March 2, 2026, the Company requested further review of the Panel’s delisting decision by the Nasdaq Listing and Hearing Review Council.
Meihua International Medical Technologies Co., Ltd. has filed a Form F-3 to register up to 520,000 Class A Ordinary Shares for resale by identified selling shareholders, from time to time after the effective date, pursuant to two share purchase agreements dated October 8, 2025 and December 5, 2025.
The prospectus states the company will receive no proceeds from these resale transactions, the shares may be sold at fixed, market-related or negotiated prices, and the company will bear registration costs. The filing notes that trading in the Class A Ordinary Shares was suspended pending a Nasdaq Hearings Panel determination after a delisting notice; the last reported sale price was $9.87 per share on February 23, 2026.